Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma

Purpose A phase 1 study evaluated the QTc prolongation potential of siltuximab, a chimeric, anti-interleukin-6 mAb, in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or low-volume MM. Methods Patients with baseline QTcF and QTcB ≤ 500 ms,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2014, Vol.73 (1), p.35-42
Hauptverfasser:	Thomas, Sheeba K., Suvorov, Alexander, Noens, Lucien, Rukavitsin, Oleg, Fay, Joseph, Wu, Ka Lung, Zimmerman, Todd M., van de Velde, Helgi, Bandekar, Rajesh, Puchalski, Thomas A., Qi, Ming, Uhlar, Clarissa, Samoylova, Olga S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacokinetics Cancer Research Electrocardiography - drug effects Humans Medicine Medicine & Public Health Middle Aged Monoclonal Gammopathy of Undetermined Significance - drug therapy Multiple Myeloma - drug therapy Oncology Original Article Pharmacology/Toxicology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose A phase 1 study evaluated the QTc prolongation potential of siltuximab, a chimeric, anti-interleukin-6 mAb, in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or low-volume MM. Methods Patients with baseline QTcF and QTcB ≤ 500 ms, QRS
ISSN:	0344-5704 1432-0843
DOI:	10.1007/s00280-013-2314-7